- Home
- NOV vs NUVL Comparison
NOV vs NUVL Comparison
Compare NOV & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOV
- NUVL
- Stock Information
- Founded
- NOV 1862
- NUVL 2017
- Country
- NOV United States
- NUVL United States
- Employees
- NOV N/A
- NUVL N/A
- Industry
- NOV Metal Fabrications
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- NOV Industrials
- NUVL Health Care
- Exchange
- NOV Nasdaq
- NUVL Nasdaq
- Market Cap
- NOV 5.6B
- NUVL 5.4B
- IPO Year
- NOV 1996
- NUVL 2021
- Fundamental
- Price
- NOV $14.56
- NUVL $85.92
- Analyst Decision
- NOV Buy
- NUVL Strong Buy
- Analyst Count
- NOV 16
- NUVL 11
- Target Price
- NOV $20.20
- NUVL $112.36
- AVG Volume (30 Days)
- NOV 3.1M
- NUVL 535.6K
- Earning Date
- NOV 02-04-2025
- NUVL 02-25-2025
- Dividend Yield
- NOV 2.06%
- NUVL N/A
- EPS Growth
- NOV 114.38
- NUVL N/A
- EPS
- NOV 2.70
- NUVL N/A
- Revenue
- NOV $8,905,000,000.00
- NUVL N/A
- Revenue This Year
- NOV $3.68
- NUVL N/A
- Revenue Next Year
- NOV $1.15
- NUVL N/A
- P/E Ratio
- NOV $5.41
- NUVL N/A
- Revenue Growth
- NOV 7.12
- NUVL N/A
- 52 Week Low
- NOV $13.95
- NUVL $61.80
- 52 Week High
- NOV $21.20
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- NOV 44.89
- NUVL 56.75
- Support Level
- NOV $14.19
- NUVL $83.71
- Resistance Level
- NOV $14.68
- NUVL $89.12
- Average True Range (ATR)
- NOV 0.45
- NUVL 3.27
- MACD
- NOV -0.04
- NUVL 1.17
- Stochastic Oscillator
- NOV 31.65
- NUVL 78.60
About NOV NOV Inc.
NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.